NVO240802P147000
- 19.80
- 0.000.00%
Novo-Nordisk A/S Newsroom
Express News | FDA Alerts Health Care Providers, Compounders, And Patients Of Dosing Errors With Compounded Injectable Semaglutide Products; Reports Of Adverse Events, Including Hospitalizations, Due To Overdoses From Miscalculation And Self-Administration Errors
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Novo Nordisk A/S – Share Repurchase Programme
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
Roche to Fast-track Weight Loss Drugs to Compete With Rivals - Report
DexCom's Stock Recorded Its Worst Selloff Ever. Not Everyone Thinks It's Justified.
Are GLP-1 Drugs Creating Headwinds for Medical Device Makers?
US FDA Flags Overdosing of Novo Nordisk's Semaglutide in Patients
Novo Nordisk Unusual Options Activity For July 26
FDA Issues Warning on Compounded Versions of Novo Nordisk's Semaglutide
EU Approves Novo Nordisk's Wegovy for Heart, Stroke Treatment
Today's Morning Movers and Top Ratings: AAPL, MMM, NVDA, COIN and More
Reduced risk of heart disease by 20%! Novo Nordisk A/S's (NVO.US) weight loss drug, Wegovy, has won a new indication in the European Union.
The European Medicines Agency (EMA) supports the use of Wegovy to reduce the risk of major cardiovascular disease and stroke in overweight or obese adults.
"Strong rivals" are coming one after the other. Eli Lilly and Co (LLY.US) has evaporated over 120 billion US dollars in market cap. Has the "Novartis duo" finally been broken?
Due to at least two competitors making encouraging progress in the treatment of obesity, Eli Lilly and Co.'s position as the leader in the weight-loss drug boom is being threatened, with market cap evaporating more than $120 billion in the past eight days.
Will it break the duopoly monopoly? The "new star" of weight loss drug Viking's stock price has doubled 2.4 times this year.
Eli Lilly and Co's market cap evaporated by 120 billion US dollars.
Novo Nordisk Shares Decline Amid Competitive Pressure
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
Novo Nordisk's Wegovy Gets EU Regulator Endorsement to Reduce Heart Risks -- Update
Novo Nordisk's weight loss drug Wegovy has received approval from the European Union and can reduce the risk of major heart diseases by 20%.
According to a press release by novo-nordisk a/s, the european medicines agency (EMA) supports the company's use of the weight-loss drug Wegovy to reduce the risk of stroke and heart disease. Analysis suggests that this significantly expands the potential number of benefiting patients.